Cannabis-Derived drug tested to ease crippling arthritis pain
NCT ID NCT05942911
Summary
This study tested whether a new combination drug called IHL-675A could safely reduce pain and improve daily function for people with rheumatoid arthritis. The drug combined two existing medications: cannabidiol (CBD) and hydroxychloroquine (HCQ). The trial compared the combination against each drug alone and a placebo, measuring changes in patient-reported pain, stiffness, and tiredness over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AusTrials Wellers Hill
Wellers Hill, Queensland, 4121, Australia
-
AusTrials Westside (Taringa)
Taringa, Queensland, 4068, Australia
-
Captain Sterling Medical Centre
Nedlands, Western Australia, 6009, Australia
-
Coast Joint Care
Maroochydore, Queensland, 4558, Australia
-
Emeritus Research
Sydney, New South Wales, 2019, Australia
-
Emeritus Research Melbourne
Camberwell, Victoria, 3124, Australia
-
Genesis Research Services
Broadmeadow, New South Wales, 2292, Australia
-
Novatrials
Kotara, New South Wales, 2289, Australia
-
Paratus Clinical (Woden Dermatology)
Phillip, Australian Capital Territory, 2606, Australia
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
Conditions
Explore the condition pages connected to this study.